sorafenib has been researched along with acarbose in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (acarbose) | Trials (acarbose) | Recent Studies (post-2010) (acarbose) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 131 | 0 | 122 |
| Protein | Taxonomy | sorafenib (IC50) | acarbose (IC50) |
|---|---|---|---|
| Alpha-amylase | Acarus siro | 3.8 | |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | 2 | |
| Pancreatic alpha-amylase | Sus scrofa (pig) | 4.3108 | |
| Alpha-amylase 1A | Homo sapiens (human) | 0.996 | |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | 2 | |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | 2 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 2 | |
| Oligo-1,6-glucosidase IMA1 | Saccharomyces cerevisiae S288C | 9.37 | |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y | 1 |
2 review(s) available for sorafenib and acarbose
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators | 2022 |